skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Trastuzumab Emtansine (Code C82492)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Trastuzumab Emtansine

Definition: An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.

Display Name: Trastuzumab Emtansine

Label: Trastuzumab Emtansine

NCI Thesaurus Code: C82492 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2935436  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Ado Trastuzumab Emtansine
Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine
Trastuzumab-MCC-DM1 Antibody-Drug Conjugate
Trastuzumab-MCC-DM1 Immunoconjugate
Trastuzumab Emtansine

External Source Codes: 
CAS Registry Number 1018448-65-1 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 564399
PDQ Open Trial Search ID 564399 (check for NCI PDQ open clinical trial info)
UMLS CUI C2935436

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For HER2-positive, metastatic breast cancer
Chemical_Formula C47H63ClN5O13S
code C82492
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Trastuzumab-MCC-DM1_Conjugate
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom